Abstract:Voltage-gated sodium channel 1.7 (Nav1.7) remains one of the most promising drug targets for pain relief. In the current study, we conducted a high-throughput screening of natural products in our in-house compound library to discover novel Nav1.7 inhibitors, then characterized their pharmacological properties. We identified 25 naphthylisoquinoline alkaloids (NIQs) from Ancistrocladus tectorius to be a novel type of Nav1.7 channel inhibitors. Their stereostructures including the linkage modes of the naphthalene group at the isoquinoline core were revealed by a comprehensive analysis of HRESIMS, 1D, and 2D NMR spectra as well as ECD spectra and single-crystal X-ray diffraction analysis with Cu K α radiation. All the NIQs showed inhibitory activities against the Nav1.7 channel stably expressed in HEK293 cells, and the naphthalene ring in the C-7 position displayed a more important role in the inhibitory activity than that in the C-5 site. Among the NIQs tested, compound 2 was the most potent with an IC 50 of 0.73 ± 0.03 μM. We demonstrated that compound 2 (3 μM) caused dramatical shift of steady-state slow inactivation toward the hyperpolarizing direction ( V 1/2 values were changed from −39.54 ± 2.77 mV to −65.53 ± 4.39 mV, which might contribute to the inhibition of compound 2 against the Nav1.7 channel. In acutely isolated dorsal root ganglion (DRG) neurons, compound 2 (10 μM) dramatically suppressed native sodium currents and action potential firing. In the formalin-induced mouse inflammatory pain model, local intraplantar administration of compound 2 (2, 20, 200 nmol) dose-dependently attenuated the nociceptive behaviors. In summary, NIQs represent a new type of Nav1.7 channel inhibitors and may act as structural templates for the following analgesic drug development.

Design, Synthesis, and Biological Evaluation of Acyl Sulfonamide Derivatives with Spiro Cycles As NaV1.7 Inhibitors for Antinociception

Identification of N-(((1S,3R,5S)-adamantan-1-yl)methyl)-3-((4-chlorophenyl)sulfonyl)benzenesulfonamide as novel Nav1.8 inhibitor with analgesic profile

Discovery of a Novel Series of Pyridone Amides As NaV1.8 Inhibitors.

Design and Synthesis of Novel Α-Aminoamides Derivatives As Nav1.7 Inhibitors for Antinociception

Discovery of selective Na V 1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain

Discovery of Selective NaV1.8 Inhibitors Based on 5-Chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl Nicotinamide Scaffold for the Treatment of Pain

Discovery of a novel series of pyridone amides as Na V 1.8 inhibitors

Synthesis and Evaluation of Novel α-Aminoamides Containing Benzoheterocyclic Moiety for the Treatment of Pain

Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel

Discovery of Indole- and Indazole-Acylsulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

2-Aminopyridines as Potent and Selective Na v 1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Nav1.7 Modulator Bearing a 3-Hydroxyindole Backbone Holds the Potential to Reverse Neuropathic Pain

Synthesis and Biological Evaluation of Novel Σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones

Recent advances in small molecule Nav 1.7 inhibitors for cancer pain management

Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1

Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.

Synthesis and Biological Evaluation of σ1 Receptor Ligands Based on Phenyl-1,2,4-oxadiazole Derivatives.

Design, synthesis, and analgesia evaluation of novel Transient Receptor Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD)

Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain